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Background: Malignant gliomas are characterized by the tendency of cancerous glial cells to infiltrate into normal
brain tissue, thereby complicating targeted treatment of this type of cancer. Recent studies suggested involvement
of Sema3C (semaphorin 3C) protein in tumorigenesis and metastasis in a number of cancers. The role of Sema3C in
gliomagenesis is currently unclear. In this study, we investigated how expression levels of Sema3C in post-operative
glioma tumors are associated with the malignancy grade and the survival of the patient.
Findings: Western blot analysis was used for detection of Sema3C protein levels in 84 different grade glioma
samples: 12 grade I astrocytomas, 30 grade II astrocytomas, 17 grade III astrocytomas, and 25 grade IV astrocytomas
(glioblastomas). Sema3C mRNA levels in gliomas were analysed by real-time PCR. Several statistical methods have
been used to investigate associations between Sema3C protein and mRNA levels and clinical variables and survival
outcome. The results demonstrated that protein levels of Sema3C were markedly increased in glioblastomas com-
pared to grade I-III astrocytoma tissues and were significantly associated with the shorter overall survival of patients.
High accumulation of Sema3C positively associated with the age of patients and pathological grade, but did not
correlate with patient’s gender. Sema3C mRNA levels showed no association with either grade of glioma or patient
survival.
Conclusions: The data presented in this work suggest that the increased levels of Sema3C protein may be
associated with the progression of glioma tumor and has a potential as a prognostic marker for outcome of glioma
patients.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1564066714158642
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Introduction
Malignant gliomas have a high proliferation rate, in-
creased angiogenesis and invasive growth. There is rarely
a clear border between the tumor and the surrounding
brain parenchyma. This imposes a problem when trying
to perform a complete surgical resection of the tumor.
As a consequence, recurrent neoplasms are established,
usually within few months after surgery, in the proximity
of the resection zone [1]. The development and* Correspondence: arunas.kazlauskas@lsmuni.lt
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unless otherwise stated.invasiveness of gliomas are under strong influence by
the local microenvironment: a plethora of factors (e.g.,
VEGF and bFGF) are secreted by tumor cells to affect
the local tissue, whereas, in response, brain parenchymal
cells secrete ligand molecules to stimulate glioma inva-
sion and/or change the local microenvironment into a
more permissive one for the tumor progression [2]. A
group of autocrine regulatory factors, semaphorins and
their receptors, neuropilins and plexins, were originally
characterized as constituents of the complex regulatory
system responsible for the guidance of axons during the
development of the central nervous system. However, a
growing body of evidence indicates that different sema-
phorins can either promote or inhibit tumor progressional. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and tumor cell survival [3]. Most of the class 3 semaphor-
ins (i.e., semaphorins 3A, 3B, 3D, 3 F and 3G) were shown
to inhibit cell migration and seem to be endowed with an-
titumor properties [4]. Meanwhile, semaphorin 3C
(Sema3C) promotes tumor migration and was highly
expressed in metastatic tumor cells [5]. There is evidence
that Sema3C also promotes endothelial cell proliferation,
migration, and tube formation in vitro and might be in-
volved in regulation of angiogenesis [6]. Recent study on
gastric cancer cells provided yet another evidence that
Sema3C assists tumor progression [4].
Regarding Sema3C association with glioma, relatively
high mRNA levels of Sema3C have been detected in a
number of glioma cell lines and also in short-term glioma
cultures derived from surgically removed tumor tissue [7].
The role of Sema3C expression in gliomas is currently un-
clear. In this study, we evaluated the Sema3C expression in
different grade glioma tissues to test our hypothesis that
Sema3C might be associated with the malignancy of this
type of tumor and patient outcome.
Materials and methods
Patients and tissue samples
Were investigated post-operative samples obtained from
84 patients diagnosed with different malignancy grade
gliomas: 12 grade I astrocytomas (pilocytic), 30 grade II
astrocytomas (diffuse), 17 grade III astrocytomas (anaplas-
tic), and 25 grade IV astrocytomas (glioblastomas). All
glioma tumor samples were collected in Neurosurgery
Clinics of Hospital (NCH) of Lithuanian University of
Health Sciences (Kaunas, Lithuania) during the period
from the year 2003 to 2012 with informed consent from
patients. Tumor samples were collected, following written
informed consent, in accordance with the Lithuanian reg-
ulations and the Helsinki Declaration. Written informed
consent was obtained for every patient under the approval
of the Ethics Committee, Lithuanian University of Health
Sciences. Database closure was in September 2013.
Diagnoses were established by pathologists at the NCH
according to the World Health Organization (WHO)
classification. Glioma samples were stored in liquid ni-
trogen before used. The following clinical data were col-
lected for each patient: age at the time of the operation,
gender, and patient status. The overall survival of the
patient was calculated from the date of the operation to
the date of death or the last recorded contact with the
live patient. None of the patients had received chemo-
therapy or radiation before surgery.
Whole-tissue extract preparation and Western blot analysis
Whole-tissue extracts of the tumor samples have been rou-
tinely prepared by resuspending the sample (100–200 μg)
in RIPA lysis buffer (50 mM Tris–HCl, pH 7.5, 150 mMNaCl, 1 % Igepal CA-630 (Sigma-Aldrich), 0.5 % sodium
deoxycolate, 0.1 % SDS) supplemented with a protease in-
hibitor cocktail (Sigma-Aldrich) and homogenizing using
an ultrasonic sonifier (500-Watt Ultrasonic Processor,
Cole-Parmer). Subsequently, the extracts were cleared by
centrifugation for 30 min at 13.000 × g at 4 °C. 80 μg of the
total extract protein were fractionated by 7.5 % SDS-PAGE
and transferred to nitrocellulose membranes. Immobilized
proteins were incubated for 2 h at 25 °C with the primary
rabbit antibody against Sema3C (C-terminus, Antibodies-
Online, catalog No. ABIN651266, dilution 1:500) in block-
ing solution (5 % nonfat milk in phosphate-buffered saline
(PBS)). After extensive washing in PBS-T buffer (PBS sup-
plemented with 0.5 % Tween-20), membranes were incu-
bated with the horseradish peroxidase- (HRP-) conjugated
anti-rabbit secondary antibody (Life Technologies, catalog
No. 656120, dilution 1:2000) for 1 h at 25 °C. For detection
of β-actin on the same membranes, the membranes were
first cleared of the Sema3C antibody complexes by washing
in the mild-striping buffer (25 mM glycine, 2 % SDS,
pH 2.0) and reprobed with the primary monoclonal mouse
antibody against β-actin (Antibodies-Online, catalog No.
ABIN559692, dilution 1:2000) for 1 h at 25 °C followed by
incubation with the HRP-conjugated anti-mouse secondary
antibody (Life Technologies, catalog No. 626520, dilution
1:2000) for 1 h at 25 °C. Immunocomplexes were visualized
using enhanced chemiluminescence reagents (Life Tech-
nologies) and documented by using gel imaging system
GelDoc-It2 (Analytika Jena AG). Values of Sema3C and β-
actin signals were calculated by using image analysis pro-
gram ImageJ (National Institutes of Health, U.S.A.).
In the experimental setup, the whole set of 84 glioma
tumor samples was organized in 6 groups each of which
containing of 16–17 tissue extracts prepared from tumors
of different malignancy grade (groups 1–4 contained sam-
ples of grades I-IV, whereas groups 5 and 6 contained only
grades II-IV due to the scarcity of the grade I and grade
III material). A separate immunoblot analysis was per-
formed on a group of samples containing arbitrarily
chosen representative samples from each of the 6 sample
groups. Sema3C signals obtained from these group repre-
sentatives were used to normalize Sema3C values (in
addition to the normalization with the β-actin values) in
all 6 membranes thereby enabling us to minimize difer-
ences between separately processed membranes. Finally,
the normalized Sema3C signal value of each tumor sample
was divided by the average signal value calculated from
the total of 84 samples resulting to the final value of the
relative Sema3C protein expression.
RNA extraction, cDNA synthesis and quantitative RT-PCR
Total RNA from cryogenically homogenized tumor tissue
was purified using TRIzol Reagent (Ambion, Life Tech-
nologies). To increase the yield of RNA, homogenate was
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sonic processor, Cole Parmer). Reverse transcription (RT)
was carried out using RevertAid H Minus M-MuLV Re-
verse Transcriptase (Thermofisher Scientific) and random
hexamer primers (Thermofisher Scientific) in a total reac-
tion volume of 20 μl according to the manufacturer’s
protocol. For inhibition of mRNA degradation RiboLock
RNase inhibitor (ThermoFisher Scientific) was used. After
synthesis cDNA stock was stored at −80 °C. Sema3C
mRNA expression was analyzed using quantitative real-
time RT-PCR SYBR Green I in 3 replicates on 7500 Fast
Real-time PCR detection system (Applied Biosystems)
and Relative Quantitation method (ΔΔCT). Reactions
have been assembled into a total volume of 12 μl, which
included: 15 ng of the cDNA, 6 μl Maxima Hot Start
PCR Master Mix (Thermofisher Scientific) with Hot
start Taq DNA polymerase, primers for SEMA3C 5′-
CAAAGATCCCACACACGGCT-3′(sense) and 5′-AC
TTGGTCCTCTGATCTCCTCC-3′(antisense, amplicon
length: 141 bp) and ACTB (encoding human β-actin)
5′-AGAGCTACGAGCTGCCTGAC-3′(sense) and 5′-
AGCACTGTGTTGGCGTACAG-3′(antisense, amplicon
length: 184 bp) to a total concentration of 0.5 μM and
0.1 μM, respectively, and nuclease-free water. PCR has
been carried out for 40 cycles consisting of 95 °C for 30 s.,
60 °C for 30 s., and 72 °C for 30 s. Fluorescent data were
converted to threshold cycle (CT) measurements. ΔΔCT
values were calculated from averaged replicates CT values
according to the formula: ΔΔCT = (ΔCTtest smaple = CT
SEMA3C – CT ACTB) – (ΔCTreference sample = CT
SEMA3C – CT ACTB). Differences between the plates
were equalized by using the reference sample (human
normal brain RNA sample, see below) Ct value realign-
ment between experiments. To be able to quantify sam-
ples in 95 % of cases, samples with standard deviation
more than 0.25 (Ct between replicates) were eliminated
from analysis. The final result was given as Log2 of
2-(ΔΔCT) calculation. Human normal brain RNA sample
“FirstChoice Human Brain Reference RNA” (Ambion,
cat. No. AM6050), which was a pool of RNAs assembled
from multiple donors from several brain regions, as de-
scribed by the manufacturer, served as a control sample
for standard curve design. Standard curve parameters
were as follows: for SEMA3C: efficiency 100.2 %, R2
0.99, slope −3.31; for ACTB: efficiency 101.2 %, R2
0.997, slope −3.29, thereby confirming the suitability of
PCR conditions and primers for mRNA quantitation
(also please see the Additional file 1: Figure S1).
Statistical analysis
SPSS Statistics 19 (SPSS Inc., Chicago, IL) software pack-
age was used for statistical analysis. Differences in Sema3C
protein and mRNA expression between different grade
groups were evaluated using the Kruskal-Wallis test.Linear correlation between Sema3C protein and mRNA
expression was examined using Spearman’s Correlation
Coefficient analysis. Associations between Sema3C protein
level and clinical features of glioma patients were analyzed
by Chi-Square Test. The Kaplan-Meier method was used
to estimate survival functions. For comparing survival
time distribution between groups the log-rank test was
used. Cox regression model was utilized to perform a
multivariate analysis. The level of significance was set to p
<0.05. False Discovery Rate (FDR) analysis was carried out
by using SPSS script designed to “Perform the Benjamini
and Hochberg FDR procedure”. Analysis showed that the
Sema3C protein expression results are still statistically sig-
nificant with the FDR criterion of 0.05.
Ethical standards
Experiments described in the manuscript comply with
the current laws of the country (Republic of Lithuania)
in which they were performed.
Results
Analyses of Sema3C expression in different grade gliomas
By using immunoblot analysis (Western blot), we aimed
to test whether expression of Sema3C at the protein level
is associated with the different histopathological grades of
glioma. For this purpose, protein extracts (whole-tissue
extracts) were prepared from 84 tumor samples of glioma
patients: 12 samples of grade I, 30 samples of grade II,
17 samples of grade III, and 25 samples of grade IV
(glioblastoma) tumors. Relative amounts of Sema3C and
β-actin (internal control) protein level in each of the ex-
tracts was determined by using Sema3C- and β-actin-
specific antibodies (Fig. 1a, also please see the Additional
file 1: Figure S2 for Sema3C protein levels in the entire set
of glioma samples). The analysis of the obtained data
demonstrated that levels of Sema3C protein in glioblast-
oma (grade IV) were significantly higher than those of the
lower grade (I–III) glioma tissues (p < 0.0001, Fig. 1b). Dif-
ferences in Sema3C protein expression were not signifi-
cant between grade I, II and III gliomas according to the
Kruskal-Wallis test (p > 0.05).
Next, we decided to examine whether there is a rela-
tionship between mRNA levels of Sema3C and malig-
nancy grade of the glioma tumor. For this purpose, we
analyzed Sema3C mRNA levels by using quantitative
real-time PCR (RT-PCR) technique on mRNA isolated
from the same set of glioma samples tha has been used
for Western blot studies except for 10 samples, which
were not included because of the scarcity of the material
or due to the exceed value of standard deviation of CT.
Sema3C mRNA values determined in 74 gliomas (9 grade
I astrocytomas, 28 grade II astrocytomas, 13 grade III as-
trocytomas, and 24 grade IV astrocytomas) were normal-
ized to mRNA levels of the β-actin-encoding gene ACTB,
Fig. 1 Protein levels of Sema3C are upregulated in glioblastoma. a Representative example of a Western blot showing Sema3C protein expression in
glioma tumor samples of differnet maligancy grades. Astrocytomas of WHO grade I, II, III, and IV (glioblastoma) are indicated as AI, AII, AIII, and GBM,
respectively. Positions of Sema3C (Sema3C), β-actin (Actin) and kDa values of the protein size marker (one before lane 1 and the second between lanes
12 and 13) are indicated. b Box plots of relative expression measurements of Sema3C obtained by Western blot analysis of astrocytoma samples. The
line inside each box represents the median, the plus symbol (+) inside the box represent the mean, and the lower and upper edges of the boxes
represent the 25th and 75th percentiles, respectively, and upper and lower lines outside the boxes represent minimum and maximum values (error
bars). The Kruskal-Wallis test shows that there are statistically significant differences of relative Sema3C expression when glioblastomas are compared
to grade I, II and III astrocytomas (p = 0.004, p < 0.0001, and p < 0.0001, respectively)
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our expectations, Sema3C mRNA levels, evaluated by
using the Kruskal-Wallis test, revealed no significant asso-
ciation with the tumor grade (Fig. 2), and there was no
linear relationship found between Sema3C mRNA and
protein levels (Spearman’s r = 0.056, p > 0.05).
Correlation of Sema3C protein level with
clinicopathological characteristics and patient survival
To determine the significance of the increased Sema3C
protein expression in glioma, we analyzed the relationship
between Sema3C protein levels and the clinicopathologi-
cal features of glioma patients. Sema3C protein level
values obtained by Western blot from the the complete
set of 84 different grade glioma samples were ranked into
three categories: values that were lower than or equal to
the 25th percentile were ranked as “low” Sema3C protein
level, values falling between the 25th and 75th percentiles
were considered as “medium” Sema3C protein level, and
values that were higher than or equal to the 75th percent-
ile were ranked as “high” Sema3C protein level. “Low”
protein levels of Sema3C were determined in 22 (26.2 %),
“medium” Sema3C levels were determined in 41 (48.8 %),
and “high” Sema3C levels were determined in 21 (25.0 %)glioma tumors. As shown in Table 1, we found positive
significant relationship between Sema3C protein level
and high tumor malignancy (p < 0.0001). This result
suggests that accumulation of high levels of Sema3C
was positively associated with the progression of glioma.
Sema3C levels also positively associated with the age of
patient (p < 0.0001), but did not correlate with gender
(p >0.05, Table 1).
The Kaplan–Meier analysis using the log-rank test was
performed to determine the association of Sema3C ex-
pression with clinical outcome of glioma patients (Fig. 3a).
The results showed that high levels of Sema3C protein in
glioma samples was markedly associated with a shorter
overall survival (p < 0.0001). Similarly, the Univariate Cox
regression analysis (Table 2) also indicated that clinical
variables including age (p < 0.0001), pathological grade
(I-II vs. III-IV WHO grade gliomas; p < 0.0001), and
Sema3C protein levels (p = 0.0001) were significantly as-
sociated with the overall survival. However, the Multi-
variate Cox regression analysis by using enter method
failed to demonstrate the level of Sema3C protein as an
independent predictor for overall survival of glioma pa-
tients (p > 0.05) suggesting that, in addition to the Sema3C
protein levels, the combination with other two clinical
Fig. 2 Relative SEMA3C mRNA expression in different malignancy
grade astrocytic gliomas. The markings of malignancy grade are the
same as in Fig. 1. Real-time PCR data shown as log2 of fold change
of SEMA3C/ACTB mRNA expression. The line inside box represent
median, the plus symbol (+) inside the box represent the mean,
and the lower and upper edges of the boxes represent 25th an 75th
percentile, respectively. Upper and lower lines outside the box
represent minimum and maximum values (error bars)
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0.0001), is critical for making predictions of the overall
survival in glioma.
We also examined how Sema3C mRNA levels reflect
upon the survival of glioma patient. The method expres-
sion level ranking (“low”, “medium”, and “high”) usedTable 1 Association of Sema3C protein level in human glioma tissu
Variable Number of cases Sema3C pro
Low n (%)
Overall 84 22 (26.2)
Age (Years)
≤50 49 19 (38.8)
>50 35 3 (8.6)
Gender
Male 38 12 (31.6)
Female 46 10 (21.8)
Pathological grade
grade I 12 5 (41.7)
grade II 30 8 (26.7)
grade III 17 8 (47.0)
grade IV 25 1 (20.0)for Sema3C protein has also been applied to mRNA
values. In contrast to Sema3C protein data, no signifi-
cant association between Sema3C mRNA level and
patient overall survival has been observed (Figure 3b,
log-rank test p > 0.05).
Discussion
Glioma is one of the most aggressive human tumors, the
prognosis of which remains extremely poor despite multi-
modal treatment by surgery, radiotherapy and chemother-
apy. Malignant glioma tumors are characterized by their
propensity towards extensive invasion into surrounding
healthy tissue and resistance to both chemo- and radiation
therapy. There is increasing interest in identification of
prognostic molecular biomarkers, which could allow to
better capture the status of tumor, provide knowledge
about glioma formation and progression and could be the
potential drug targets. The process of tumor cell invasion
is a complex combination of cellular and molecular events
involving the breakdown of extracellular matrix (ECM)
components, cell detachment, and migration through the
basement membrane and stroma [8]. Semaphorins were
initially characterized as regulators of cell migration that
play role in repulsive axon guidance but are now recog-
nized as key players in morphogenesis and homeostasis
over a wide range of organ systems [9]. A growing body of
evidence indicates that various semaphorins can modulate
tumor progression through either promotion or inhibition
of processes such as tumor angiogenesis, tumor metastasis
and cancer cell survival [3]. Semaphorin 3C is a member
of the class 3 family of secreted semaphorins that are
known to play important roles in regulating neuronal as
well as vascular patterning [10], mesenchymal cell
differentiation, and neural crest cell migration [11]. In
addition, Sema3C is a positive regulator of endotheliales with different clinicopathological features
tein level p-value
Medium n (%) High n (%)
41 (48.8) 21 (25.0)
27 (55.1) 3 (6.1) 0.0001
14 (40.0) 18(51.4)
19 (50.0) 7 (18.4) 0.37
22 (47.8) 14 (30.4)
7 (58.3) 0 (0.0) 0.0001
18 (60.0) 4 (13.3)
8 (47.0) 1 (6.0)
8 (16.0) 16 (64.0)
Fig. 3 Kaplan-Meier survival curves representing the overall survival of glioma patients. The whole set of glioma samples stratified by relative
protein or mRNA levels to “low”, “medium”, and “high” level categories, as described in the text above. a The relationship between the protein
level of Sema3C and patient survival. N = 84, log-rank test, χ2 = 29.931; df = 2, p < 0.0001. b The relationship between the mRNA level of Sema3C
and patient survival. N = 74, log-rank test, χ2 = 0.115; df = 2, p = 0.944
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hesion, migration, and tube formation in vitro by stimu-
lating integrins and VEGF secretion [6]. Taking into
account this functional background of Sema3C, perhaps
it is not surprising to witness an increasing number of
studies showing that aberrant expression levels of this
protein is associated with a number of cancer pheno-
types. It has been shown, for example, that Sema3C is
highly expressed in several human cancer types. The ex-
pression of Sema3C was found to be upregulated in meta-
static cells of lung adenocarcinoma [12]. High Sema3C
expression increased motility and invasion of prostate
cancer cells [13], whereas in ovarian cancer high levels of
Sema3C were associated with shorter patient survival [14].
A very recent study has demonstrated that Sema3C signal-
ing could play a role as a central regulator of glioma stem
cell survival and glioblastoma progression via activation of
the Rac1/NF-κB signaling pathway [15].
With regard to Sema3C expression in gliomas, one of
the prominent studies on this topic reported high Sema3C
mRNA expression in the majority of the tested glioma cell
lines and primary glioma cell cultures derived from surgi-
cally removed tumor tissue [7]. Experiments conducted byTable 2 Cox regression analysis for glioma patients (n = 84)
Variable Univariate
HR 95 % CI
Age (years) 1.062 1.045-1.080
Gender (female vs. male) 0.904 0.582-1.404
WHO grade (I-II vs. III-IV) 4.879 2.892-8.231
SEMA3C protein level
low (reference) - -
medium 0.756 0.336-1.703
high 3.613 1.638-7.969Man and colleagues showed strong Sema3C staining
compared to normal human brain tissue in a subpopula-
tion of glioblastoma cells [15]. In the same laboratory, a
microarray anaylsis of glioblastoma tissues revealed that
Sema3C was overexpressed in a subpopulation of tumor
cells in 30 out of 35 (85.7 %) cases but was barely de-
tectable in normal brain tissue [15]. Our study for the
first time examined Sema3C expression at protein levels
in astrocytoma tissues of different malignancy grade.
We observed a marked increase of Sema3C in glioblast-
omas compared to lower grade (i.e., WHO grades I, II,
and III) astrocytomas (Fig. 1) indicating that the aber-
rant expression of Sema3C may be strongly associated
with the advancement of glioma malignancy. Sema3C
upregulation was distinctly associated with the poor
prognosis in glioma patients, especially with high WHO
grade (Fig. 3a). However, the real-time PCR analysis of
the same set of glioma samples showed no association
between Sema3C mRNA levels and malignancy grade of
the tumor (Fig. 2) as well as patient survival (Fig. 3b).
This result, although different from the observations
mentioned earlier in this section [7, 15], should not be
seen as a surprise because the issue regarding theMultivariate
p-value HR 95 % CI p-value
<0.0001 1.064 1.034-1.095 <0.0001
0.654
<0.0001 4.081 1.918-8.682 <0.0001
- - - -
0.500 0.545 0.234-1.268 0.159
0.001 0.826 0.313-2.183 0.700
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not been resoved yet. For example, Laffaire and col-
leagues by using genomic methylation and comparative
gene expression profiles found that SEMA3C gene is
differentially methylated in both low-grade gliomas and
glioblastomas compared with normal brain controls.
SEMA3C methylation frequency has been determined
in 72 % of low-grade gliomas and in 56 % of glioblast-
omas [16], whereas the gene expression data placed
SEMA3C among genes that were prominently downreg-
ulated in gliomas. However, the validation of experi-
mental data on SEMA3C with the TCGA (The Cancer
Genome Atlas) glioblastoma data set revealed different
pattern of expression and methylation of SEMA3C,
thus, leaving the question regarding SEMA3C expres-
sion in gliomas open [16]. In any case, we would like to
stress here that we do not rule out the involvement of
the transcriptional regulation of the SEMA3C gene in the
process of gliomagenesis since, given the heterogeneuos
composition of glioma tumor (especially high grade), it is
plausible that the active SEMA3C transcription might be
going on in a specific subpopulation of cells, such as gli-
oma stem cells [15]. Expression of Sema3C in those cells
has been demonstrated to be important for growth and in-
vasion of the glioma tumor [15].
While searching for alternative explanations of the in-
crease of Sema3C levels in high grade gliomas, we would
like to point out that the most predominant 70 kDa
Sema3C isoform in our immunoblots most likely repre-
sents the cleavage product of Sema3C generated by one
of the proteases (e.g., furin-like pro-protein convertase
(FPPC) [17] since the full-length Sema3C protein has
been reported of 95 kDa in size, which was detected in
the human breast cancer cell line MCF7 [5]. Therefore,
we suggest the possibility that the high accumulation of
Sema3C in glioblastomas may be the result of: i) lower
activity of certain Sema3C-targetting protease(s) com-
pared to lower grade astrocytomas or ii) the higher de-
gree of protection of Sema3C against ECM proteases
while being in a complex with cell surface receptors
(neuropilins, plexins [3, 15]) in glioblastomas. The no-
tion that Sema3C processing may differ between glioma
grades is at some extent supported by our observation
that a short, approximately 45 kDa fragment, which was
recognized by Sema3C antibody in immunoblots, ap-
peared more often in grade I-III astrocytoma samples ra-
ther than in glioblastomas (Additional file 1: Figure S3).
The importance of the site-specific processing of secreated
semaphorins for their function has been demonstrated in
a number of studies. For example, Sema3 proteins possess
from one to three furin consensus sequences (RXRR), the
cleavage at which, in cases of Sema3A and Sema3F, are
critical for binding to neuropilin-1 and inducing antian-
giogenic effects on endothelial cells [18, 17]. The cleavageof the short basic domain at the C-terminal portion of
Sema3C by metalloproteinase ADAMTS1 seem to be im-
portant for Sema3C-dependent induction of endothelial
cell migration, whereas Sema3C processing to a short p65
isoform by FPPC renders it inactive [5]. Moreover, the
FPPC cleavage-resistant Sema3C has been shown to in-
hibit proliferation and migration of lymphatic endothelial
cells and human umbilical vein endothelial cells [19]. We
do not know whether the 70 kDa isoform of Sema3C de-
tected in our immunoblots corresponds to the inactive
p65 protein or, on the contrary, represents a hitherto
uncharacterized biologically active form of Sema3C. This
particular and other important questions regarding role
Sema3C in gliomagenesis should be addressed in the
future studies.
Conclusion
Findings presented in our study show that the increased
protein level of Sema3C is associated with the progression
of glioma malignancy and poor patient survival. Further
investigation will be required to evaluate Sema3C value as
a molecular marker of glioma prognoses.
Additional file
Additional file 1: This additional file includes supplementary
figures S1-S3.
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